We had previously shown that it is possible to detect somatic mutations in about 60% of MS patient blood samples, and that the mutations were mostly (85%) discovered in CD8+ cells in comparison to other, CD4+ or CD19+ cells. This evidence concerns the gene CD8A and myeloid sarcoma.